AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28181118
Drug: Flutemetamol F
RxNorm normalized name: Flutemetamol F18
DrugBank: Flutemetamol (18F) (DB09151)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Flutemetamol F 18 Injection (185 MBq)
Trial: 28181933
Drug: Severe intraoperative
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe intraoperative hyperglycemia (SIH, blood glucose ≥180 mg/dL)
Trial: 28182762
Drug: High 2'FL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High 2'FL concentration (1880-2460 mg/L)
Trial: 28182762
Drug: Low 2'FL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low 2'FL concentration (12-42 mg/L)
Trial: 28183713
Drug: Vaccination targeting
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination targeting native receptors
Trial: 28185288
Drug: Metformin (2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2,000 mg/day for 9 or more days prior to surgery)
Trial: 28186982
Drug: AvidinOX anchorage
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AvidinOX anchorage with biotinylated antibodies
Trial: 28187404
Drug: Potentized estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potentized estrogen (12cH, 18cH and 24cH) administered twice daily per oral route for 24 weeks
Trial: 28188000
Drug: Structured program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured program for β-blocker titration with up-titration visits every 2 weeks after implantation (target dose: 10mg/day of bisoprolol or 50mg/day of carvedilol).
Trial: 28188000
Drug: Remote monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote monitoring for 66 patients in Study Group with daily transmission of weight and blood pressure data.
Trial: 28188239
Drug: No immunosuppressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immunosuppressant
Trial: 28188773
Drug: Maternal buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maternal buprenorphine administration
Trial: 28188907
Drug: NEO6860 (TRPV1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NEO6860 (TRPV1 antagonist)
Trial: 28190158
Drug: Ketamine mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine mouthwash 20 mg/5 mL four times daily
Trial: 28190704
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiation therapy (photon radiation therapy)
Trial: 28191026
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g Flaxseed Fiber (FF) with Orlistat
Trial: 28191026
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg Dairy Calcium (Ca) with Orlistat
Trial: 28191034
Drug: Integrated treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatments plus a once-daily multivitamin
Trial: 28192114
Drug: Sirolimus and
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus and hydroxychloroquine (200 mg twice a day)
Trial: 28192114
Drug: Sirolimus and
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus and hydroxychloroquine (400 mg twice a day)
Trial: 28192597
Drug: Cabozantinib (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib (60 mg orally and daily on a continuous schedule)
Trial: 28193194
Drug: Falls surveillance
RxNorm normalized name: Halls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Falls surveillance with monthly calendars and telephone interviews
Trial: 28193515
Drug: Not exposed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not exposed to biologics (Control)
Trial: 28193678
Drug: Aspirin desensitization
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin desensitization protocol (5.5 hours)
Trial: 28193678
Drug: Aspirin desensitization
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin desensitization protocol
Trial: 28194232
Drug: Post-challenge OGTT
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-challenge OGTT 2 h insulin in CSX
Trial: 28194232
Drug: Post-challenge OGTT
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-challenge OGTT 2 h insulin in CAD
Trial: 28194232
Drug: Fasting glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose, insulin, HOMA-IR in CSX
Trial: 28194232
Drug: Fasting glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting glucose, insulin, HOMA-IR in CAD
Trial: 28194539
Drug: Pimasertib (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimasertib (45 mg/day) plus Temsirolimus (25 mg/week)
Trial: 28196056
Drug: Dexamethasone intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone intravitreal implant (DEX; Ozurdex 700 μg) administered immediately after cataract surgery
Trial: 28196270
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg twice weekly for 12 weeks, followed by 50 mg weekly
Trial: 28196715
Drug: Killed oral
RxNorm normalized name: Hongo Killer
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Killed oral cholera vaccine (OCV), Shanchol™
Trial: 28196905
Drug: DHP107, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP107, a novel oral paclitaxel formulation, 200 mg/m
Trial: 28196905
Drug: DHP107, a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHP107, a novel oral paclitaxel formulation, 150-250 mg/m
Trial: 28197031
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oral diclofenac 1 hour before procedure (Group A)
Trial: 28199478
Drug: Topical carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical carmustine and intravenous O6-benzylguanine
Trial: 28199478
Drug: Dual-dose O6-benzylguanine
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dual-dose O6-benzylguanine plus carmustine
Trial: 28199478
Drug: Single-dose O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose O6-benzylguanine and carmustine
Trial: 28202056
Drug: 400 ml
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 ml 12.6% carbohydrate-rich drink
Trial: 28202638
Drug: Single-Dose Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Dose Supplementation
Trial: 28203424
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with paclitaxel and cisplatin plus McKeown esophagectomy with total two-field lymphadenectomy
Trial: 28204726
Drug: Qutenza® (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qutenza® (topical capsaicin 8%)
Trial: 28205038
Drug: Loxapine for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxapine for inhalation
Trial: 28205231
Drug: ctDNA presence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ctDNA presence monitoring after chemotherapy
Trial: 28207791
Drug: 25(OH)D concentrations
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D concentrations of 40 to 49.99 nmol/L
Trial: 28207791
Drug: 25(OH)D concentrations
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D concentrations of 30 to 39.99 nmol/L
Trial: 28207791
Drug: 25(OH)D concentrations
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D concentrations of <30 nmol/L
Trial: 28207791
Drug: 25(OH)D concentrations
RxNorm normalized name: 1α,25(OH)2D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25(OH)D concentrations of 75 to 99.99 nmol/L
Trial: 28207791
Drug: High 25(OH)D
RxNorm normalized name: HIGH DENSITY POLYETHYLENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High 25(OH)D levels up to 125 nmol/L
Trial: 28207896
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Serpinb6b (granzyme A inhibitor)
Trial: 28209218
Drug: NOAC (non-vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC (non-vitamin K antagonist oral anticoagulants)
Trial: 28210662
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA) 40 mg/mL 3-times-weekly formulation (GA40)
Trial: 28213596
Drug: Total white
RxNorm normalized name: Colgate Total Whitening
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total white cell count (WBC) within the normal range (8.65-10.05×10^9/L)
Trial: 28213684
Drug: Community-based chronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based chronic care overweight and obesity treatment
Trial: 28213914
Drug: Chronic autonomic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS) at 10 Hz, 250 μs pulse width, 18% duty cycle, maximum tolerable current amplitude after 10 weeks of titration
Trial: 28213914
Drug: Chronic autonomic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic autonomic regulation therapy (ART) with vagus nerve stimulation (VNS)
Trial: 28213943
Drug: Elotuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elotuzumab (10 mg/kg, accelerated infusion over ∼1 h), combined with lenalidomide (25 mg daily, Days 1-21) and dexamethasone (28 mg orally and 8 mg intravenously, weekly, Cycles 1-2; 40 mg orally, weekly, Cycles 3+)
Trial: 28213943
Drug: Elotuzumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elotuzumab (10 mg/kg, standard infusion over ∼3 h), combined with lenalidomide and dexamethasone (from previous phase 3 study)
Trial: 28214655
Drug: Eribulin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin treatment
Trial: 28215251
Drug: Caffeine consumption
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine consumption in CC genotype
Trial: 28215851
Drug: Neoadjuvant Stereotactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Stereotactic Body Radiotherapy (SBRT) at escalating doses (35, 40, 45, and 50 Gy) in 10 daily fractions
Trial: 28215937
Drug: Evolocumab 420
RxNorm normalized name: evolocumab 420 in 3.5 ML Cartridge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 420 mg subcutaneously monthly (or every 2 weeks if on apheresis)
Trial: 28215937
Drug: Evolocumab (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (increased dosing to every 2 weeks)
Trial: 28218593
Drug: In-car video
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-car video feedback intervention (3 months of intervention with weekly reports, DVD of unsafe events, and telephone contacts)
Trial: 28219694
Drug: Lenalidomide 25
RxNorm normalized name: lenalidomide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25 mg per day for 21 of 28 days until lymphoma progression or unacceptable toxicity
Trial: 28219925
Drug: Consistent long-term
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consistent long-term heavy alcohol intake >112 g of ethanol/week
Trial: 28221823
Drug: MiniMed 640G
RxNorm normalized name: homatropine hydrobromide Ophthalmic Solution [Minims Homatropine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MiniMed 640G 'suspend before low' feature set at 65 mg/dL, predicting hypoglycemia and suspending insulin delivery when glucose was predicted to be ≤85 mg/dL.
Trial: 28222073
Drug: Oral rucaparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rucaparib (240 mg per day) combined with carboplatin (AUC 5 mg/ml)
Trial: 28222073
Drug: Intravenous rucaparib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous rucaparib combined with various chemotherapy regimens (carboplatin, carboplatin/paclitaxel, cisplatin/pemetrexed, epirubicin/cyclophosphamide)
Trial: 28225505
Drug: Conventional optimal
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional optimal medical therapy
Trial: 28228461
Drug: Residual inflammatory
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residual inflammatory risk (hsCRP >3 mg/L)
Trial: 28229893
Drug: Natalizumab 300
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab 300 mg intravenous
Trial: 28231807
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of direct and indirect measures of adiposity
Trial: 28235011
Drug: Type of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type of cancer therapy
Trial: 28235771
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with histamine dihydrochloride (HDC) and low-dose IL-2
Trial: 28235848
Drug: LQT2 patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LQT2 patients underwent a 6-hour 75-g oral glucose tolerance test with ECG recording and blood sampling.
Trial: 28235848
Drug: Control participants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control participants underwent the same 6-hour 75-g oral glucose tolerance test.
Trial: 28238593
Drug: Lapatinib (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1000 mg per day orally) and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks intravenously) for 18 weeks; hormone receptor-positive patients received letrozole (2·5 mg per day orally) or tamoxifen (20 mg per day orally).
Trial: 28238631
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of QHPV
Trial: 28238631
Drug: 4 doses
RxNorm normalized name: parathyroid hormone 25 MCG/Dose Cartridge, 14 Doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 doses of QHPV
Trial: 28239491
Drug: Travoprost 0.004%/Timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004%/Timolol 0.5% fixed-dose combination
Trial: 28240822
Drug: Recombinant Sfrp3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Sfrp3 treatment in myotubes from lean insulin-sensitive subjects
Trial: 28240822
Drug: LPS or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS or recombinant IL-6 treatment in in vitro-differentiated myotubes
Trial: 28241770
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of tobacco use treatment guidelines using the Consolidated Framework for Implementation Research (CFIR)
Trial: 28241807
Drug: High-dose external
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose external beam radiation therapy (RT)
Trial: 28241824
Drug: Autologous Platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Platelet Rich Plasma (PRP) injections and topical application of PRP gel
Trial: 28241824
Drug: Autologous Platelet
RxNorm normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous Platelet Rich Plasma (PRP) injections
Trial: 28243404
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic therapy for CINV
Trial: 28243577
Drug: Idursulfase treatment
RxNorm normalized name: Idursulfase
DrugBank: Idursulfase (DB01271)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Idursulfase treatment
Trial: 28245821
Drug: Higher tertiles
RxNorm normalized name: textiles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher tertiles of GDF-15 (mean GDF-15 was 1,304 pg/mL)
Trial: 28246291
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A injections, 155 units administered every 12 weeks
Trial: 28248702
Drug: Norepinephrine 3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 3, 4, 5, 6, 7, or 8 µg IV bolus
Trial: 28249145
Drug: Lentiviral vector-mediated
RxNorm normalized name: Autologous CD34+ cells transduced with lentiviral vector which encodes for the aryl Sulfatase A complimentary deoxyribonucleic acid sequence
DrugBank: Atidarsagene autotemcel (DB17538)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentiviral vector-mediated addition of an antisickling β-globin gene into autologous hematopoietic stem cells; details on dosage and duration not available.
Trial: 28249145
Drug: Busulfan conditioning;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan conditioning; details on dosage and duration not available.
Trial: 28249841
Drug: Bivalent virus-like
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent virus-like particle (VLP) vaccine (GI.1/GII.4) administered intramuscularly.
Trial: 28250200
Drug: Vismodegib (Hh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vismodegib (Hh inhibitor) treatment in cancer patients
Trial: 28254126
Drug: CRT-ON (Cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-ON (Cardiac Resynchronization Therapy ON)
Trial: 28254126
Drug: CRT-D (Cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT-D (Cardiac Resynchronization Therapy with defibrillator)
Trial: 28254203
Drug: Minimal caregiver
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal caregiver worry about medication adverse effects
Trial: 28254869
Drug: Selective radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective radiotherapy dose increase to hypoxic tumor areas, details on dosage and duration not specified.
Trial: 28256358
Drug: MVA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA vaccine subcutaneously by S&N on Days 1 and 29 (standard)
Trial: 28256358
Drug: MVA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA vaccine subcutaneously by S&N on Days 1 and 15
Trial: 28256358
Drug: MVA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA vaccine subcutaneously by S&N on Days 1 and 22
Trial: 28256358
Drug: MVA vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA vaccine subcutaneously by JI on Days 1 and 29
Trial: 28257602
Drug: Temporary steroids
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temporary steroids while background immunosuppressants were withdrawn
Trial: 28257602
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy resumed when symptoms recurred
Trial: 28261651
Drug: Pazopanib 400
RxNorm normalized name: PAZOPanib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 400 mg daily + Cisplatin 75 mg/m²
Trial: 28261656
Drug: BIW-8962 (monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIW-8962 (monoclonal antibody to GM2 ganglioside)
Trial: 28262342
Drug: Aspirin +
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin + dipyrone
Trial: 28262724
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist monotherapy
Trial: 28264796
Drug: Jawbone Up24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jawbone Up24 monitor, tablet with Jawbone Up app, brief weekly telephone counseling for 12 weeks
Trial: 28264833
Drug: No anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticoagulant treatment (no AC)
Trial: 28265478
Drug: Twice-daily pramipexole
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily pramipexole extended release (PER) regimen
Trial: 28265478
Drug: Once-daily pramipexole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily pramipexole extended release (PER) regimen
Trial: 28265861
Drug: Human urinary
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human urinary kallidinogenase (HUK) administered by intravenous drip once daily for 21 consecutive days
Trial: 28266092
Drug: HPV-16/18 AS04-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 AS04-adjuvanted vaccine (3 doses at 0, 1, and 6 months)